Stocks
Artiva Biotherapeutics, Inc.ARTV
NASDAQHealthcareBiotechnology$6.15
Price as of · delayed, not real-time
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell therapies for autoimmune diseases and cancers. Its lead candidate, ARTIV-1, is in Phase 1/2 trials for systemic lupus erythematosus and lupus nephritis. Investors track the stock for its potential in the emerging allogeneic cell therapy space, though clinical readouts remain the primary catalyst.
52W Range: $2.96-$14.53
Congressional Interest in Artiva Biotherapeutics, Inc. (ARTV)
No congressional trades have been disclosed for Artiva Biotherapeutics, Inc. (ARTV) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ARTV?
No congressional trades found for this stock.